Fatigue is well known to occur in chronic inflammatory diseases, such as multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Similarly, it occurs in patients with cancer [
26,
27]. Fatigue is hypothesized to be mediated by inflammatory cytokines [
28] and an activated Th1-immune system [
29], primarily through the brain–gut axis. The brain–gut axis is the bidirectional pathway between the central and enteric nervous system, mediated by the HPA axis. Pro-inflammatory cytokines, in response to environmental or clinical stress, activate the HPA axis through secretions of corticotropin-releasing factor (CRF) from the hypothalamus. CRF then stimulates the adrenocorticotropic hormone (ACTH) from the pituitary gland, which then stimulates the release of cortisol, a stress hormone, from the adrenal gland [
30]. Cortisol has systemic effects and can affect the brain, resulting in fatigue [
30].
Multiple studies have shown that fatigue is associated with clinically active IBD. In a single-center cross-sectional study, it was discovered that 48.7% of the 187 patients with IBD suffered from fatigue. After adjustment for age and sex, fatigue was inversely associated with clinical and endoscopic but not histological remission [
7]. In a larger study of the Inflammatory Bowel Disease in South-Eastern Norway (IBSEN) cohort, of the 440 patients with IBD who had disease for at least 20 years and completed the FQ, those with clinically active disease had higher fatigue scores than those with inactive disease (UC 17.1 versus 12.4,
p < 0.001, and CD 17.5 versus 13.3,
p < 0.001) [
6]. In a study of patients with IBD in clinical remission, the number of memory T cells and neutrophils was significantly higher (
p = 0.005 and 0.033, respectively), while that of monocytes was lower (
p = 0.011) in those with fatigue (
n = 55) compared with those without fatigue (
n = 29), as measured by the CIS-fatigue scale. Additionally, the levels of inflammatory cytokines such as tumour necrosis factor alpha (TNFα), interferon-γ (IFNγ), interleukin-12 (IL-12), and IL-10 were significantly higher and IL-6 lower, suggesting differences in immunological activity between the two groups [
29]. Furthermore, longitudinal data over 2 years from the Manitoba IBD cohort (
n = 312) revealed that fatigue was strongly associated with inflammation [
5]. In a study of 67 children with IBD, those in the lowest insulin-like growth factor I (IGF-1)
z score quartile had significantly greater fatigue (
p = 0.02), as well as higher levels of IL-10, IL-17A, IL-6, and IFNγ [
31] implicating inflammatory pathways in fatigue pathogenesis. However, these studies did not determine endoscopic or biochemical remission, making it difficult to determine underlying IBD-related inflammatory burden accurately. One study (
n = 288), in which fatigue was assessed during active disease and during deep remission, those in deep remission had no significant difference in immune markers, i.e., calprotectin, C-reactive protein (CRP), IL-17A, IL-6, IL-1β, IL-10, IL-8, TNFα, IL-13, IFN, IL-4, and IL-12, between those with fatigue and those without fatigue [
9]. Thus, in quiescent disease, inflammation may not have a significant role in the pathogenesis of fatigue. However, active IBD with elevated cytokines, such as TNFα and IFNγ, as well as elevated fecal calprotectin, correlates with the severity of fatigue [
5,
6,
9,
29,
32‐
34].
Inflammation is associated with a greater catabolic state and increase in resting energy expenditure, which could contribute to fatigue. In a study of 75 adult patients with CD, those with active disease had higher resting energy expenditure (REE) than those in remission (28.8 ± 5.4 vs 25.9 ± 4.3 kcal/kg,
p < 0.001) [
35]. Furthermore, pro-inflammatory cytokines can lead to anorexia and a decrease in caloric intake [
36], dysregulation of the HPA axis [
37], and promote anxiety and depressive symptoms through the gut–brain axis in susceptible persons [
38], which could be perceived as fatigue.
While most studies note an association of inflammation and fatigue, there is heterogeneity among published studies. In a study by Villoria et al., among 202 patients with IBD in clinical remission, there was no correlation between levels of CRP, IL-5, IL-8, and IL-12 and fatigue scores, although fatigue was prevalent in 54% of the cohort. However, in this study, endoscopic inflammation and calprotectin were not provided. The mean CRP in all three groups (none, mild, and severe fatigue) was normal and with a wide standard deviation [
39]. A second prospective study of 544 patients with IBD found that fatigue was associated with anxiety, depression, and sleep disorders, but not associated with disease activity. This study, however, defined active disease in CD as a Harvey–Bradshaw index score greater than 4 points. This scoring system is based on factors including abdominal pain, abdominal mass, and complications such as arthralgia. It does not take into account objective measures of active disease, such as CRP, fecal calprotectin, endoscopic markers, of inflammation [
40].